^
    Back
    Association details:
    Biomarker:STK11 underexpression + PD-L1 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    In Vivo
    Title:

    Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer

    Excerpt:
    From February 2017 to January 2020, we retrospectively analyzed 30 previously untreated patients with NSCLC and a tumor proportion score (TPS) ≥50% treated with pembrolizumab monotherapy....The disease progression rate for the low-STK11/LKB1 group was higher than that of the high-STK11/LKB1 group.
    DOI:
    10.21873/invivo.12131